Literature DB >> 11887493

Arterial endothelin-1 in interstitial lung disease patients with pulmonary hypertension.

G Trakada1, K Spiropoulos.   

Abstract

The aim of this study was to evaluate the plasma arterial levels of Endothelin-1 (ET-1) and their relationship with hypoxia and pulmonary hypertension (PH) in patients with interstitial lung disease (ILD). Incremental cycle ergometry was performed in all patients up to maximal capacity. ET-1 levels during exercise (2.2 +/- 0.36 pgr/ml) were significantly higher than at rest (1.73 +/- 0.37 pgr/ml) (p < 0.001). ET-1 levels were also significantly correlated with arterial oxygen (PaO2) (r = -0.935, p < 0.001) and mean pulmonary arterial pressure (Ppa) (r = 0.657, p < 0.001). Increased pulmonary and peripheral blood levels of ET-1 have been described in, and postulated to contribute to, the pathophysiology of several lung diseases. In agreement with this, in the current study, the plasma arterial levels of ET-1 were also found to be significantly elevated in patients with various interstitial lung disorders during exercise, especially in those with severe hypoxia and pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11887493

Source DB:  PubMed          Journal:  Monaldi Arch Chest Dis        ISSN: 1122-0643


  3 in total

1.  Endothelin-1 levels in interstitial lung disease patients during sleep.

Authors:  Georgia Trakada; Eugenia Nikolaou; Athanasia Pouli; Maria Tsiamita; Kostas Spiropoulos
Journal:  Sleep Breath       Date:  2003-09       Impact factor: 2.816

2.  Plasma endothelin-1 and vascular endothelial growth factor levels and their relationship to hemodynamics in idiopathic pulmonary fibrosis.

Authors:  Corey E Ventetuolo; Steven M Kawut; David J Lederer
Journal:  Respiration       Date:  2012-08-03       Impact factor: 3.580

3.  Pulmonary hypertension in parenchymal lung disease.

Authors:  Iraklis Tsangaris; Georgios Tsaknis; Anastasia Anthi; Stylianos E Orfanos
Journal:  Pulm Med       Date:  2012-10-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.